Univariate analysis identified male sex, age ≥60 years, myeloid malignancies, B-cell lymphoma, other lymphoid malignancies, bendamustine use, anti-CD20 antibody use, and anti-CD38 antibody use as statistically significant risk factors (P<0.01 for all). This evidence concerns the gene CD38 and myeloid neoplasm.